What is GT Biopharma Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. GT Biopharma's interest expense for the
three
months ended in Jun. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. GT Biopharma's Operating Income for the
three
months ended in Jun. 2024 was $ -3.91 Mil. GT Biopharma's Interest Expense for the
three
months ended in Jun. 2024 was $ 0.00 Mil.
GT Biopharma has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
GT Biopharma Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GT Biopharma (NAS:GTBP) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
GT Biopharma's Interest Expense for the
three
months ended in Jun. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Jun. 2024 was $-3.91 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Jun. 2024 was $0.00 Mil.
GT Biopharma's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as
| GT Biopharma had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. GT Biopharma Inc has enough cash to cover all of its debt. Its financial situation is stable.
GT Biopharma Business Description
Traded in Other Exchanges
N/A
Address
8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Executives
| Charles J Casamento |
director |
99 BELBROOK WAY, ATHERTON CA 94027 |
| Michael Martin Breen |
director, officer: Exec. Chair. and Interim CEO |
LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU |
| Manu Ohri |
officer: CFO & Secretary |
2355 MAIN STREET, SUITE 120, IRVINE CA 92614 |
| Bruce Wendel |
director |
70 ELEVEN O'CLOCK ROAD, WESTON CT 06883 |
| Gregory Berk |
officer: Pres. of R&D, CMO |
HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080 |
| Shrotriya Rajesh C Md |
director |
157 TECHNOLOGY DRIVE, IRVINE CA 92618 |
| Alan Louis Urban |
director |
1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404 |
| Gavin Choy |
officer: Acting Chief Financial Officer |
8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005 |
| Steven W Weldon |
director, officer: CFO |
7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835 |
| Shawn Cross |
director, officer: Chief Executive Officer |
1825 K STREET SUITE 510, WASHINGTON DC 20006 |
| Raymond W. Urbanski |
officer: Chief Medical Officer |
28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
| Kathleen Clarence-smith |
director, 10 percent owner, officer: CEO |
1623 31ST STREET NW, WASHINGTON DC 20007 |
| Mark J Silverman |
10 percent owner |
224 22ND ST., SANTA MONICA CA 90402 |
| Bristol Capital Llc |
10 percent owner |
|
| Bristol Investment Fund Ltd |
10 percent owner |
89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GTBP has been successfully added to your 